Nyah Phengsitthy

Washington, D.C., United States

Health Reporter at Bloomberg Law

Reporting on FDA, drug pricing and health care @blaw | ✉️: [email protected] | Signal: andnyahknow.01

Articles

RFK Jr. Puts Health Insurers in Limbo by Dropping Covid-19 Shot

1 week ago | news.bloomberglaw.com | Nyah Phengsitthy |Lauren Clason

Insurers still analyzing Kennedy’s move to pull vaccinePlans in ‘gray area’ for keeping, cutting coverageUS Heath Secretary Robert F. Kennedy Jr.’s decision to pull the Covid-19 vaccine from the CDC’s recommended immunization list for healthy children and pregnant women means health plans must navigate whether to keep providing coverage for the shot.
RFK Jr. Puts Health Insurers in Limbo by Dropping Covid-19 Shot

1 week ago | news.bloombergtax.com | Nyah Phengsitthy |Lauren Clason

US Health Secretary Robert F. Kennedy Jr.’s decision to pull the Covid-19 vaccine from the CDC’s recommended immunization list for healthy children and pregnant women means health plans must navigate whether to keep providing coverage for the shot.
Trump’s Drug Price Plan Seeks Leverage With FDA Withdrawal Power

1 week ago | news.bloombergtax.com | Nyah Phengsitthy

President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to revoke drug approvals if manufacturers don’t meet pricing targets under the plan, a provision that is likely to face fierce legal resistance from industry if applied. Trump’s executive order signed earlier this month revives his “most favored nation” policy that seeks to slash US drug costs by directing manufacturers to match prices to the lowest ones paid in other countries.
Trump’s Drug Price Plan Seeks Leverage With FDA Withdrawal Power

1 week ago | news.bloomberglaw.com | Nyah Phengsitthy

Executive order directs agency to pull, modify approvalsRegulator’s authority is unclear under pricing policyPresident Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to revoke drug approvals if manufacturers don’t meet pricing targets under the plan, a provision that is likely to face fierce legal resistance from industry if applied.
FDA’s Device Center Rejects Data From Two Facilities in China

2 weeks ago | news.bloomberglaw.com | Nyah Phengsitthy

May 22, 2025, 6:59 PM UTC Nyah Phengsitthy Reporter The Food And Drug Administration headquarters in White Oak, Md. Photographer: Sarah Silbiger/Getty Images Third-party testing companies falsified data, agency says Regulator ramps up efforts to address data integrity concerns The FDA’s device center denied data from two third-party testing companies in China due to falsified or invalid information, the latest move from the agency to address concerns around the integrity of data coming from...
NIH Faces Skeptical Judge in Fight Over Slashed Research Grants

2 weeks ago | news.bloombergtax.com | Nyah Phengsitthy

A federal judge wrestled Thursday with the NIH’s reasons for terminating hundreds of research grants that are no longer in line with the Trump administration’s priorities. “DEI grant, what does that mean?” Judge William G. Young for the US District Court for the District of Massachusetts said about terminated grants that related to diversity, equity, and inclusion. “I wrestle with this,” Young told the US government.
NIH Faces Skeptical Judge in Fight Over Slashed Research Grants

2 weeks ago | news.bloomberglaw.com | Nyah Phengsitthy

Court presses parties on diversity, equity, inclusion meaningAgency slashed funds for research on cancer, HIV preventionA federal judge wrestled Thursday with the NIH’s reasons for terminating hundreds of research grants that are no longer in line with the Trump administration’s priorities. “DEI grant, what does that mean?” Judge William G. Young for the US District Court for the District of Massachusetts said about terminated grants that related to diversity, equity, and inclusion.
Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit

2 weeks ago | news.bloombergtax.com | Nyah Phengsitthy

Bristol Myers Squibb Co. and Novartis AG are seeking to revive lawsuits in the DC Circuit after a federal judge struck down claims that a US health agency acted unlawfully when it didn’t approve their proposals to discount medicines through a rebate model.
Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit

2 weeks ago | news.bloomberglaw.com | Nyah Phengsitthy

and are seeking to revive lawsuits in the DC Circuit after a federal judge struck down claims that a US health agency acted unlawfully when it didn’t approve their proposals to discount medicines through a rebate model.
FDA Issues Generic Drug Development Guidance to Support Approval

2 weeks ago | news.bloombergtax.com | Nyah Phengsitthy

The FDA issued 48 product-specific guidance documents on Tuesday that outline the agency’s recommendations for developing generic drugs that treat asthma, allergic reactions, and chronic obstructive pulmonary disease. The draft product-specific guidances, or PSGs, target medicines that are expected to be therapeutically equivalent to certain drugs, according to the Food and Drug Administration.